TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy

NCT03394118 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Osimertinib

Sponsor

Asan Medical Center

Collaborators

[object Object]